CASI Pharmaceuticals, Inc. announced appointment of Daniel Lang, MD as Senior vice president of the company, effective July 8, 2024. Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capital and Chief Investment Officer at RS Investments Value Group.

Most recently, he was the President of Athenex cell therapy division and led clinical development of the NKT cell platform.